# Suppression of Endogenous Glucose Production by Injectable HDV-Insulin Lispro: A Dose Response Study in Human Subjects With Type 1 Diabetes

> **NCT05689424** · PHASE1 · NOT_YET_RECRUITING · sponsor: **University of California, San Diego** · enrollment: 18 (estimated)

## Conditions studied

- Type 1 Diabetes

## Interventions

- **DRUG:** HDV-Insulin Lispro

## Key facts

- **NCT ID:** NCT05689424
- **Lead sponsor:** University of California, San Diego
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-02-01
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2024-10-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05689424

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05689424, "Suppression of Endogenous Glucose Production by Injectable HDV-Insulin Lispro: A Dose Response Study in Human Subjects With Type 1 Diabetes". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05689424. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*